Document is current
Any future updates will be listed below
-
Authors
Li, Zhihong
Tsai, Hsiao-Kuei https://orcid.org/0009-0005-9322-9019
Libby, Adam H.
Founds, Michael W.
Murtagh, Olivia L. https://orcid.org/0009-0000-1352-4477
Ware, Madeleine L.
Leace, David M. https://orcid.org/0000-0002-9198-3481
Wolfe, Wesley J.
Gingrich, Phillip W. https://orcid.org/0000-0002-6110-5434
Al-Lazikani, Bissan
Chang, Chin-Yuan https://orcid.org/0000-0001-7314-3967
Hsu, Ku-Lung https://orcid.org/0000-0001-5620-3972
-
Funding
Funding for this research was provided by:
Cancer Prevention and Research Institute of Texas (RR220063)
Welch Foundation (F-2143-20230405)
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (T32GM139796)
- License Information
-
More Information
Article History
Received: 16 July 2025
Accepted: 4 May 2026
First Online: 5 June 2026
Competing interests
: K.-L.H. is a founder and scientific advisory board member of Hyku Biosciences. A patent application (WO 2025/240977 A1) has been filed by the University of Texas at Austin covering the SuPUR chemistry platform for ligand discovery targeting ABAD, ABHD10, PARP2, and ACAT2 presented in this manuscript. The remaining authors declare no competing interests.
